News

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.

The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

Some patients with the condition may experience exacerbation or new onset.

Let us know what content you want to see from RAD.

Using mass spectrometry, researchers examined novel changes to gather updated metastasis information.

Results of a new study indicate that baricitinib offers a potential therapeutic option with a favorable benefit-risk profile for pediatric patients with moderate-to-severe AD.

Inhibitor etanercept alleviated pathological changes and inflammation in induced psoriasis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of April.

The results of a new study reveal that the the antibody works by activating the immune response to fight cancer and slows melanoma growth in mice.

Physical activity and exercise may lead to improved mental health but exacerbate skin conditions.

Galderma announced the approval of a injectable poly-L-lactic acid to correct fine lines and wrinkles.

Patients more commonly reported skin aging manifestations when they experienced higher levels of stress.

In this week’s Pointers with Portela, the 208SkinDoc explains why vitamin C serums can occasionally have an unpleasant smell.